These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 19505410)

  • 21. Efficacy of etanercept in the treatment of a patient with Behçet's disease.
    Curigliano V; Giovinale M; Fonnesu C; Cerquaglia C; Verrecchia E; Turco S; Manganelli C; Manna R
    Clin Rheumatol; 2008 Jul; 27(7):933-6. PubMed ID: 18330611
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis.
    Saurenmann RK; Levin AV; Rose JB; Parker S; Rabinovitch T; Tyrrell PN; Feldman BM; Laxer RM; Schneider R; Silverman ED
    Rheumatology (Oxford); 2006 Aug; 45(8):982-9. PubMed ID: 16461435
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Etanercept and uveitis in patients with juvenile idiopathic arthritis.
    Schmeling H; Horneff G
    Rheumatology (Oxford); 2005 Aug; 44(8):1008-11. PubMed ID: 15855187
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists.
    Williams VL; Cohen PR
    Int J Dermatol; 2011 May; 50(5):619-25. PubMed ID: 21506984
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.
    Calvo-Río V; Blanco R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Hernandez Garfella M; Valls Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero Coma M; Díaz-Llopis M; Gallego R; Salom D; García Serrano JL; Ortego N; Herreras JM; Fonollosa A; García-Aparicio AM; Maíz O; Blanco A; Torre I; Fernández-Espartero C; Jovani V; Peiteado-Lopez D; Pato E; Cruz J; Fernández-Cid C; Aurrecoechea E; García M; Caracuel MA; Montilla C; Atanes A; Hernandez FF; Insua S; González-Suárez S; Sánchez-Andrade A; Gamero F; Linares L; Romero-Bueno F; García AJ; Almodovar R; Minguez E; Carrasco Cubero C; Olive A; Vázquez J; Ruiz Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernández S; Rueda-Gotor J; González-Gay MA
    Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Etanercept for psoriasis in the pediatric population: experience in nine patients.
    Hawrot AC; Metry DW; Theos AJ; Levy ML
    Pediatr Dermatol; 2006; 23(1):67-71. PubMed ID: 16445417
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Etanercept in severe, recalcitrant psoriasis: clinical response, safety profile and predictors of response based on a single institution's experience.
    Antoniou C; Dessinioti C; Stratigos A; Avgerinou G; Stavropoulos P; Katsambas A
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):979-82. PubMed ID: 19470056
    [No Abstract]   [Full Text] [Related]  

  • 28. The use of biologic agents in the treatment of ocular manifestations of Behcet's disease.
    Benitah NR; Sobrin L; Papaliodis GN
    Semin Ophthalmol; 2011; 26(4-5):295-303. PubMed ID: 21958178
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.
    Gerloni V; Pontikaki I; Gattinara M; Fantini F
    Ann Rheum Dis; 2008 Aug; 67(8):1145-52. PubMed ID: 17981916
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Behçet's syndrome: from aetiology to treatment.
    Powell RJ
    Adv Exp Med Biol; 2003; 528():481-6. PubMed ID: 12918749
    [No Abstract]   [Full Text] [Related]  

  • 31. TNF-alpha antagonists for the treatment of juvenile-onset spondyloarthritides.
    Homeff G; Burgos-Vargas R
    Clin Exp Rheumatol; 2002; 20(6 Suppl 28):S137-42. PubMed ID: 12463465
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Behçet's disease and the possibilities of modern tumour necrosis factor inhibiting medication].
    van Laar JA; Jamnitski A; Baarsma GS; van Daele PL; van Hagen PM
    Ned Tijdschr Geneeskd; 2006 Apr; 150(13):705-9. PubMed ID: 16623340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A case of mucocutaneous Behçet's disease responding to etanercept.
    Sommer A; Altmeyer P; Kreuter A
    J Am Acad Dermatol; 2005 Apr; 52(4):717-9. PubMed ID: 15793540
    [No Abstract]   [Full Text] [Related]  

  • 34. Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis--data from the dutch arthritis and biologicals in children register, 1999-2010.
    Otten MH; Prince FH; Twilt M; Ten Cate R; Armbrust W; Hoppenreijs EP; Koopman-Keemink Y; Wulffraat NM; Gorter SL; Dolman KM; Swart JF; van den Berg JM; van Rossum MA; van Suijlekom-Smit LW
    J Rheumatol; 2011 Oct; 38(10):2258-63. PubMed ID: 21844151
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey.
    Foeldvari I; Nielsen S; Kümmerle-Deschner J; Espada G; Horneff G; Bica B; Olivieri AN; Wierk A; Saurenmann RK
    J Rheumatol; 2007 May; 34(5):1146-50. PubMed ID: 17343318
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Septic abscess in a child with juvenile idiopathic arthritis receiving anti-tumor necrosis factor-alpha.
    Fitch PG; Cron RQ
    J Rheumatol; 2006 Apr; 33(4):825; author reply 826-7. PubMed ID: 16583487
    [No Abstract]   [Full Text] [Related]  

  • 37. [Psoriasis and psoriatic rheumatism: effectiveness of etanercept for cutaneous and joint lesions].
    Paul C; Solignac M
    Ann Dermatol Venereol; 2010 Apr; 137(4 Suppl):13-5. PubMed ID: 20510165
    [No Abstract]   [Full Text] [Related]  

  • 38. [Experience with an anti-TNFalpha in rheumatology].
    Goupille P
    Ann Dermatol Venereol; 2005; 132(8-9 Pt 2):4S10-4S12. PubMed ID: 16335347
    [No Abstract]   [Full Text] [Related]  

  • 39. Etanercept treatment in corticosteroid-dependent myasthenia gravis.
    Rowin J; Meriggioli MN; Tüzün E; Leurgans S; Christadoss P
    Neurology; 2004 Dec; 63(12):2390-2. PubMed ID: 15623708
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection.
    Carroll MB; Bond MI
    Semin Arthritis Rheum; 2008 Dec; 38(3):208-17. PubMed ID: 18221983
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.